louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00227214: Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.
Official title: Prevalence of Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pneumococcal Meningitis
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2005-09-27
Enrollment: 160
Sex: ALL
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children from 0 up to 14 years of age with a diagnosis of confirmed or probable pneumococcal meningitis or with a diagnosis of suspected bacterial meningitis without bacterial or viral isolation.

Brief summary: The aim of this study is to determine the prevalence of pneumococcal meningitis in the paediatric population in Spain four years after the marketing of Prevenar. Also secondary objectives are: 1) to determine the clinical characteristics and outcome of the disease; and 2) to determine serotypes and antibiotic resistance patterns.


Eligibility criteria: Inclusion Criteria:

* All children from 0 up to 14 years with diagnosis of confirmed or probable pneumococcal meningitis or with diagnosis of suspected bacterial meningitis without bacterial or viral isolation will be included into the study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Alcalá de Henares
country: Spain
city: Alcorcón
country: Spain
city: Badalona
country: Spain
city: Barakaldo
country: Spain
city: Barcelona
country: Spain
city: Barco de Valdeorras
country: Spain
city: Bilbao
country: Spain
city: Boadilla del Monte
country: Spain
city: CEE
country: Spain
city: Esplugues de Llobregat
country: Spain
city: Estella
country: Spain
city: Ferrol
country: Spain
city: Figueres
country: Spain
city: Getafe
country: Spain
city: Girona
country: Spain
city: Granollers
country: Spain
city: La Coruña
country: Spain
city: Leganés
country: Spain
city: Lleida
country: Spain
city: Lugo
country: Spain
city: Madrid
country: Spain
city: Mondragón
country: Spain
city: Monforte de Lemos
country: Spain
city: Móstoles
country: Spain
city: Ourense
country: Spain
city: Pamplona
country: Spain
city: Pontevedra
country: Spain
city: Reus
country: Spain
city: Ribeira
country: Spain
city: Sabadell
country: Spain
city: San Lorenzo de El Escorial
country: Spain
city: San Sebastián
country: Spain
city: Tarragona
country: Spain
city: Terrasa
country: Spain
city: Tudela
country: Spain
city: Verín
country: Spain
city: Vigo
country: Spain
city: Vitoria
country: Spain
city: Zumárraga
country: Spain
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06909214: A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
Official title: A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: New Onset Generalized Myasthenia Gravis (gMG)
Lead sponsor: argenx
Sponsor class: INDUSTRY
First posted: 2025-04-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.


Eligibility criteria: Inclusion Criteria:

* Is at least 18 years when signing the ICF
* Has been diagnosed with gMG of MGFA class II, III, or IV
* Is seropositive for AChR-Ab
* Is treatment-naive for gMG or has been administered AChEI for the treatment of gMG
* Had onset of generalized MG signs and/or symptoms within 12 months before screening; candidates who also had onset of ocular MG signs and/or symptoms within 24 months before screening may be enrolled in the study
* Has an MG-ADL score ≥5

Exclusion Criteria:

* gMG diagnosis of MGFA class I or V
* Underwent a thymectomy prior to screening, except thymectomy for treatment of nonmalignant thymoma prior to the gMG diagnosis
* Prior or current use of any of any systemic corticosteroid therapy or nonsteroidal immunosuppressive therapy for the treatment of gMG

Primary outcomes:
measure: Proportion of participants who achieve MSE of MG at any time within the first 16 weeks of treatment with efgartigimod PH20 SC
timeFrame: up to 16 weeks
Secondary outcomes:
measure: Changes from baseline in MG-ADL total scores over time
timeFrame: up to 51 weeks
measure: Changes from baseline in MG-QOL-15r total scores over time
timeFrame: up to 51 weeks
measure: Proportion of participants who are administered systemic corticosteroid therapy as background add-on therapy throughout the study
timeFrame: up to 55 weeks
measure: Incidence of adverse events, serious adverse events and adverse events leading to study drug discontinuation
timeFrame: up to 55 weeks
Other outcomes:
Locations:
city: Boca Raton
country: United States
facility: EZR Research
state: Florida
Study officials:
References:
Clinical trial NCT05015114: Prevalence and Factors of Sarcopenia and in Patients With Primary Sjogren's Syndrome
Official title: Prevalence and Factors of Sarcopenia in Patients With Primary Sjogren's Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sarcopenia
Sjogren's Syndrome
Rheumatologic Disease
Lead sponsor: Acibadem University
Sponsor class: OTHER
First posted: 2021-08-20
Enrollment: 50
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with primary Sjogren's syndrome

Brief summary: Sarcopenia is a progressive condition characterized by decline in muscle strength and muscle mass. Although the mechanism of sarcopenia has not been fully elucidated, it may be caused by protein-poor diet, vitamin D deficiency, hormonal changes, increase in inflammatory cytokine level and oxidative stress. For this reason, it is thought that determining the prevalence of sarcopenia in rheumatological diseases with chronic inflammation and protecting patients from possible comorbidities with appropriate interventions may be an important factor in maintaining and improving the functional levels and quality of life of patients.

The aim of our study was to investigate the prevalence and its associated factors of sarcopenia in individuals with primary Sjögren's Syndrome.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with primary Sjogren's syndrome by an experienced rheumatologist according to European League Against Rheumatism (EULAR) ve American College of Rheumatology (ACR) criteria
* Being 40 years or older.

Exclusion Criteria:

* Pregnancy,
* Malignancy,
* Presence of other rheumatological diseases,
* Presence of diabetes mellitus
* Presence of neurological problems
* Presence of osteoarthritis

Primary outcomes:
measure: Muscle Mass
timeFrame: 1 day
measure: Grip Strength
timeFrame: 1 day
measure: Gait Speed
timeFrame: 1 day
measure: 5 Times Sit to Stand Test
timeFrame: 1 day
Secondary outcomes:
measure: EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)
timeFrame: 1 day
measure: EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI)
timeFrame: 1 day
measure: Malnutrition Evaluation
timeFrame: 1 day
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Haydarpasa Numune Research and Training Hospital
Study officials:
References:
Clinical trial NCT06742255: Stellate Ganglion Block in Longstanding Facial Nerve Palsy Patients
Official title: Stellate Ganglion Block in Longstanding Facial Nerve Palsy Patients
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Stellate Ganglion
Facial Palsy
Pain Management
Keywords: Stellate gangliom
Facial palsy
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-12-19
Enrollment: 34
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: facial nerve palsy patients

Brief summary: The goal of the present study is to verify the efficacy of stellate ganglion block (SGB) in the treatment of facial pain


Eligibility criteria: Inclusion Criteria:

* facial nerve palsy patients

Exclusion Criteria:

1. light of a recent myocardial infarction.
2. anticoagulant use
3. glucoma
4. lateral nerve palsy
5. emphysema
6. cardiac conduction abnormalities
7. active infection, flu, cold
8. uncontrolled cough
9. Fever
10. Very high blood pressure or if you are on blood thinners.
11. allergic reaction to local anesthetics
12. Primary and secondary coagulopathy.

Primary outcomes:
measure: Primary outcome: Average motor conduction latency in six muscle of the face
timeFrame: 6 month
Secondary outcomes:
measure: Improved muscle tone
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
References:
citation: Piraccini E, Munakomi S, Chang KV. Stellate Ganglion Blocks. 2023 Aug 13. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK507798/
citation: Wang D. Image Guidance Technologies for Interventional Pain Procedures: Ultrasound, Fluoroscopy, and CT. Curr Pain Headache Rep. 2018 Jan 26;22(1):6. doi: 10.1007/s11916-018-0660-1.
citation: Kapral S, Krafft P, Gosch M, Fleischmann D, Weinstabl C. Ultrasound imaging for stellate ganglion block: direct visualization of puncture site and local anesthetic spread. A pilot study. Reg Anesth. 1995 Jul-Aug;20(4):323-8.
citation: Abdi S, Zhou Y, Patel N, Saini B, Nelson J. A new and easy technique to block the stellate ganglion. Pain Physician. 2004 Jul;7(3):327-31.
citation: Baig S, Moon JY, Shankar H. Review of Sympathetic Blocks: Anatomy, Sonoanatomy, Evidence, and Techniques. Reg Anesth Pain Med. 2017 May/Jun;42(3):377-391. doi: 10.1097/AAP.0000000000000591.
Clinical trial NCT00266955: Retrospective of Children With ADHD and Cardiac Symptoms
Official title: A Retrospective Study of Children With ADHD and Cardiac Symptoms
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Congenital Disorders
Keywords: pediatric
cardiac
ADHD
Adderall
Straterra
Lead sponsor: Children's Healthcare of Atlanta
Sponsor class: OTHER
First posted: 2005-12-20
Enrollment: 10
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: retro chart review

Brief summary: There is some evidence suggesting ADHD medication interaction could result in mild myocardial ischemia/infarct.

Detailed description: Children with no previous cardiac history who have been on Adderall for ADHD, have developed acute cardiac symptoms after the addition of Straterra for the treatment of ADHD.

We wish to do a study of the medication interactions of Straterra and other ADHD medications focusing on the cardiac manifestations.

We will collect the following information on each patient: Medical Record Number, Account number, Dates of Admission, Discharge, Treatment or Death, Information Regarding Cardiac Signs and Symptoms, Medication Information, Age, Weight, Diagnoses

Eligibility criteria: Inclusion Criteria:

* ADHD
* myocardial ischemia/infarct
* no previous cardiac history
* added Straterra
* already taking Adderall

Exclusion Criteria:

* those who do not meet inclusion criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Children's Healthcare of Atlanta
state: Georgia
Study officials:
affiliation: Children's Healthcare of Atlanta
name: Martha Clabby, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02569255: Safe Use of New Oral Anticoagulants in Ablation for Atrial Fibrillation
Official title: Safe Use of New Oral Anticoagulants in Patients Treated by Catheter Ablation for Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Lead sponsor: Private Hospital Heart Center Varde
Sponsor class: OTHER
First posted: 2015-10-06
Enrollment: 234
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with paroxysmal or persistent atrial fibrillation and symptomatic despite pharmacological treatment.

Brief summary: Use of new oral anticoagulants (NOAC) in patients before and after catheter based pulmonary vein isolation (PVI) is still controversial. Experience is reported from consecutive patients ablated with PVI for atrial fibrillation and treated with dabigatran, rivaroxaban, or apixaban from Nov 2011 until Dec 2014. Patients are followed for 3 month after ablation. All complications possible being related to the use of NOAC are registered.

Detailed description: Use of new oral anticoagulants (NOAC) in patients before and after radiofrequency ablation with pulmonary vein isolation (PVI) is still controversial. Experience is reported from consecutive patients ablated with PVI for atrial fibrillation and treated with dabigatran, rivaroxaban, or apixaban from Nov 2011 until Dec 2014. Patients paused their NOAC treatment for 24 hours before ablation. Patients were routinely followed up after 3 months with a standard formular focused on possible adverse events (major bleeding complications or thromboembolic events) to NOAC treatment. Adverse events related to the use of NOAC were registered during treatment or during 3 months of follow-up.

Eligibility criteria: Inclusion Criteria:

* Symptomatic atrial fibrillation despite pharmacological treatment.

Exclusion Criteria:

* None

Primary outcomes:
measure: Number of participants with bleeding or thromboembolism during PVI and/or three months of follow up
timeFrame: Up to three months after PVI
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Varde Heart Center
name: Peter S Hansen, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05075655: Endobronchial Diagnosis of Lymphoma
Official title: Diagnosis of Lymphoma Using Endobronchial Ultrasound Guided Miniforceps Biopsy.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Lymphoma
Keywords: ebus
endobronchial ultrasound-guided
EBUS-MFB
intra-nodal miniforceps biopsy
EBUS-transbronchial forceps biopsy
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
First posted: 2021-10-13
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: DIAGNOSTIC

Brief summary: The present study aimed to assess the diagnostic performance of ultrasound-guided endobronchial intra-nodal miniforceps biopsy (EBUS-MFB) in the diagnosis of "de novo" mediastinal lymphoma.

Detailed description: Every patients will be sampled using both EBUS-MFB and the standard of care EBUS-TBNA (transbronchial needle aspiration).

It is a monocentric investigation. Pathologist will not know the way of sampling while analysing the samples

Eligibility criteria: Inclusion Criteria:

* Pathological mediastinal nodes within reach of EBUS sampling on CT-scan.
* Lymphoma suspicion by a senior clinical hematologist
* Affiliated to the french public health care insurance

Exclusion Criteria:

* Peripherical pathological lymph nodes reachable without general anesthesia
* Antithrombotic medication that cannot be stopped le time of the procedure.
* Unstable respiratory status
* History of lymphoma
* Latex or xylocaine allergia

Primary outcomes:
measure: positivity of the procedure in Diagnosis and Subtyping of lymphoma
timeFrame: up to 3 years
Secondary outcomes:
measure: every adverse effect related to the procedure
timeFrame: up to 3 years
Other outcomes:
Locations:
city: Caen
country: France
facility: CaenUH
state: Normandy
Study officials:
References:
Clinical trial NCT05659355: Effects of Constraints Induced Movement Therapy Versus Mirror Therapy in Children With Hemiplegic Cerebral Palsy
Official title: Effects of Constraints Induced Movement Therapy Versus Mirror Therapy on Hand Dexterity and Grip Strength in Children With Hemiplegic Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cerebral Palsy
Hemiplegic Cerebral Palsy
Keywords: cerebral palsy
constraints induced movement therapy
mirror therapy
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-12-21
Enrollment: 18
Sex: ALL
Minimum age (years): 9
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to find Effects of constraints induced movement therapy (CIMT) versus mirror therapy (MT) on hand dexterity and grip strength in children with hemiplegic cerebral palsy.

Detailed description: Although quite number of research has been done on effects of CIMT and mirror therapy but most of the studies included stroke population. There was no literature on comparative effect of both CIMT and Mirror therapy in children with hemiplegic cerebral palsy. This study will be covering specifically cerebral palsy children to have better treatment techniques to be introduced in therapeutic programs of hemiplegic cerebral palsy children.

Eligibility criteria: Inclusion Criteria:

* Children of age range 9-14 year
* Children with diagnosed hemiplegic cerebral palsy
* Children who can perform active extension of affected wrist and more than
* two fingers at an angle of more than 10 degrees
* Active abduction of affected thumb at an angle of 10 degrees
* Children who can respond to simple communication-

Exclusion Criteria:

* Children with uncontrolled seizures
* Botulinum toxin injections or orthopedic surgery in the upper or lower
* extremities within the previous 12 months or planned within the study period
* Children with depression who were unable to cooperate in treatment
* Children who are unable to perform active task training

Primary outcomes:
measure: 9 Hole pegboard test:
timeFrame: 3 months
measure: Haptic (Tactile) Recognition Test:
timeFrame: 3 months
measure: Hand Dynamometer:
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Mobility Quest
state: Punjab
Study officials:
affiliation: Riphah International University
name: Shabana Ashraf
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02149355: Teeth and Jaw Misalignment in Patients Suffering From Congenital Fourth Cranial Nerve Palsy
Official title: Teeth and Jaw Misalignment in Patients Suffering From Congenital Fourth Cranial Nerve Palsy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Fourth Cranial Nerve Palsy
Keywords: teeth position
jaw alignment
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2014-05-29
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients suffering from congenital fourth nerve palsy

Brief summary: Patients suffering from congenital fourth cranial nerve palsy may have misalignment of jaws as well as teeth due to head tilt in childhood.

Detailed description: Measurement of teeth and jaw parameters in patients suffering from congenital fourth cranial nerve palsy compared to patients without fourth cranial nerve palsy.

Eligibility criteria: Inclusion Criteria:

* unilateral congenital fourth nerve palsy
* natural teeth occlusion
* age \> 18 years

Exclusion Criteria:

* bilateral fourth nerve palsy
* no natural teeth occlusion

Primary outcomes:
measure: angle between teeth positions from upper and lower jaw
timeFrame: 3 to 6 months after recruitment
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: UniversityHospital Zurich
state: ZH
Study officials:
affiliation: University Hospital Zurich, ophthalmology department
name: Klara Landau, Prof MD
role: STUDY_CHAIR
References:
Clinical trial NCT01520155: CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE)
Official title: CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE): Studie Zur Detektion Des kardiovaskulären Risikos in Patienten Mit Systemischem Lupus Erythematodes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Systemic Lupus Erythematosus
Keywords: lupus erythematosus
cardiovascular risk
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2012-01-27
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with or without systemic Lupus erythematosus

Brief summary: The key of this prospective study is to identify a potentially increased cardiovascular risk in patients with systemic Lupus erythematodes, with and without renal affection. Three groups of patients will be compared.

Detailed description: Key of this prospective study is to identify a potentially increased cardiovascular risk in patients with systemic Lupus erythematodes, with and without renal affection. Three group of patients will be compared as followed. First group are patients with known systemic Lupus erythematodes without renal affection, second group are patients with known systemic Lupus erythematodes with renal affection and the third group are patients with a non-autoimmun chronic kidney disease

Eligibility criteria: Inclusion Criteria:

* Patients with systemic Lupus erythematosus

Exclusion Criteria:

* Patients without systemic Lupus erythematosus

Primary outcomes:
measure: Identification of cardiovascular risk in patients with systemic Lupus Erythematodes
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Frankfurt am Main
country: Germany
facility: Frankfurt University Academic Medical Center
state: Hessen
Study officials:
affiliation: Frankfurt University Academic Medical Center
name: Joachim R Ehrlich, MD
role: STUDY_CHAIR
References: